&w=3840&q=100)
Prostate cancer scare in 2020 turned out to be 'false alarm' for singer Shaan
Prostate cancer scare five years ago compelled noted playback singer Shaan to go for a check-up, which then confirmed that it was just a 'false alarm'.
Sharing his experience at the launch of MenCan, an initiative of Urologic Oncology Disease Management Group (URO DMG), a unit of the Tata Memorial Centre (TMC) here, he also urged people to get medical tests done, saying health was of utmost importance.
'I had a bit of a prostate scare in 2020, which I want to share with you. It almost led to a point where I was told by a few doctors that this could be prostate cancer, but it turned out it was a false alarm,' he told reporters.
STORY CONTINUES BELOW THIS AD
'Since then, I've been very, very careful in terms of getting my regular tests done. And that is something that I've done on a personal level, which again, when I share with my friends, it's very ticklish, it's very funny. Therefore, I realised that it's something that we need to, you know, create more awareness,' he said.
The voice behind countless hits such as 'Tanha Dil', 'Musu Musu Hasi', 'Jab Se Tere Naina' and 'Chand Sifarish', is now going to be the brand ambassador for MenCan initiative.
MenCan is a non-profit and non-commercial initiative that will address the challenges of prostate, penile and testicular cancers in men.
Shaan said there are certain taboos, stigmas and fear attached to the word cancer. 'The word itself, people don't want to use it, like it's almost like a scary word,' he said.
According to him, he quickly agreed to become the brand ambassador for MenCan because there is a taboo in the society about openly talking about prostate, testicular or penile cancer.
'You don't want to be forthcoming about it. Get yourself checked, get yourself administered because it feels kind of violated, scary. But we have to get over that because at the end of the day, your health, especially a man's health, is important. If a man is not in his best health, it's going to affect the family,' he said.
STORY CONTINUES BELOW THIS AD
'We need to talk about it. We need to bring awareness. And so I'm very happy that though I'm completely a lay person in the medical and scientific world, if I can be of any use, if I've been chosen to do this, I'll do my utmost to support MenCan,' he added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indian Express
5 days ago
- Indian Express
Revolutionising disease's treatment: Twin study identifies novel risk genes, molecular subtypes in thyroid cancer among Indians
In a significant leap for cancer research and precision medicine, a twin Indian study has decoded the complex genetic architecture of thyroid cancer — one of the most common endocrine malignancies. Researchers from Tata Memorial Centre and the Department of Genetics, University of Delhi, South Campus, have shed new light on how thyroid cancer behaves in Indian patients, identifying novel risk genes and molecular subtypes that could revolutionise diagnosis and treatment. Both the studies were published back-to-back in 'JCO Global Oncology.' The research is spearheaded by graduate student Vaishakhi Trivedi under the mentorship of Dr Kumar Prabhash and Dr Amit Dutt. 'Our work not only adds data to global cancer databases — it also redefines what is known about thyroid cancer in the Indian population,' Professor Dutt said. The first study concerns papillary thyroid cancer (PTC), which accounts for 80-85 per cent of all thyroid cancer cases in India. This is considered treatable. The team analysed DNA from 100 Indian patients and found mutations in the DUOX2 gene found in nearly nine per cent of cases. 'This gene, previously known for its role in thyroid hormone production, now appears to be a genetic red flag for recurrence and poor prognosis. This is the first time DUOX2 has been implicated as a predisposing factor in PTC. It offers an opportunity for early detection and potentially life-saving interventions,' Prof Dutt said. The study even identified two different subtypes associated with aggressive cancer and high recurrence. The BRAF-RAS-driven subtype makes up 62 per cent of cases and is identified by mutations that are often tied to more aggressive tumour behaviour. The iBR (Independent of BRAF-RAS) subtype is a newly-defined category. 'This group lacks traditional mutations but shows alarming signs of treatment resistance and high recurrence. It is marked by alterations in genes like SMAD4 and TG — a previously uncharted territory for thyroid oncologists,' said Dr Prabhash. This dual classification signals a new era of care where treatments are tailored to the patient's genetic profile rather than a one-size-fits-all approach. While PTC is common and often curable, anaplastic thyroid cancer (ATC) is its deadly cousin — rare, fast-moving and resistant to nearly every treatment in the book. In a separate study, the research team examined 68 samples and found mutations in the THRA gene in 11 per cent of Indian patients with ATC. This is in sharp contrast to Caucasian datasets. 'THRA, a gene tied to thyroid hormone signalling, appears to be a key player in cellular plasticity or the process by which cancer cells morph, lose their identity and become more aggressive. THRA mutations are like flipping the switch. They make the cancer harder to kill but they also give us a target. That's a rare silver lining,' Dr Prabhash explained. These findings offer practical methods of how thyroid cancers are diagnosed, treated and managed in Indian patients. 'Patients with DUOX2 mutations could be monitored proactively, much like BRCA testing in breast cancer. This may help in diagnosing aggressive PTC and ATC early and prevent a relapse,' Prof Dutt said. Researchers also added that therapies that restore THRA function may finally give ATC patients a fighting chance. 'We need a personalised roadmap for thyroid cancer. With the promise of advanced tools like CRISPR gene editing and small-molecule inhibitors, these discoveries could soon migrate from the lab bench to the bedside,' the researchers said. 'Genetic profiling should be as routine as a biopsy,' said Vaishakhi Trivedi. 'We have the science. Now we need the systems to support it.' Anuradha Mascarenhas is a journalist with The Indian Express and is based in Pune. A senior editor, Anuradha writes on health, research developments in the field of science and environment and takes keen interest in covering women's issues. With a career spanning over 25 years, Anuradha has also led teams and often coordinated the edition. ... Read More
Time of India
24-07-2025
- Time of India
Short-staffed cancer units: Rights panel seeks answers
Chandigarh: Taking suo motu cognisance of a Times of India report, the Punjab State Human Rights Commission (PSHRC) has sought an explanation from the state health department over the acute shortage of medical professionals at three premier cancer care institutions in Punjab . The TOI report, published on July 23, highlighted alarming staff vacancies at Govt Medical College, Amritsar; Tertiary Care Cancer Centre (TCCC) at Civil Hospital, Fazilka; and two hospitals run by the Tata Memorial Centre - Homi Bhabha Cancer Hospital (HBCH), Sangrur, and Homi Bhabha Cancer Hospital & Research Centre (HBCH&RC), New Chandigarh. At Govt Medical College, Amritsar, only 19 of the 43 sanctioned posts are filled, leaving 24 posts (55.81%) vacant. These include all senior resident positions in radiotherapy, multiple vacancies in surgical oncology, and complete staff shortages in the nuclear medicine and medical oncology departments. At Civil Hospital, Fazilka, only four of 28 sanctioned posts (14.28 per cent) are filled. The hospital lacks professors and associate professors in radiotherapy and surgical oncology, and preventive oncology is short of even an assistant professor. The situation is equally dire at the Tata Memorial Centre-run facilities. Out of 637 sanctioned posts across HBCH Sangrur and HBCH&RC New Chandigarh, 393 posts (61.69%) remain vacant. These include serious gaps in medical, scientific, technical, and nursing staff, with 223 nursing positions unfilled out of a sanctioned 340. The commission also noted that despite an earlier direction in a case order dated June 23, no report was submitted by the directorate health. "Neither any communication nor the required report has been received," the commission observed. The commission has now granted a final opportunity to the directorate health to submit the report at least one week before the next date of hearing. Failing this, the director health will be required to appear in person and explain why action under Section 16 of the Protection of Human Rights Act should not be initiated.
Indian Express
23-07-2025
- Indian Express
Indian study finds what makes thyroid cancer aggressive, recurrent and treatment-resistant: What this means for precision therapy
In a significant leap for cancer research and precision medicine, an Indian study has decoded the complex genetic architecture of thyroid cancer — one of the most common endocrine malignancies. Researchers from Tata Memorial Centre and the University of Delhi, South Campus, have shed new light on how thyroid cancer behaves in Indian patients, identifying novel risk genes and molecular subtypes that could revolutionise diagnosis and treatment. Published in 'JCO Global Oncology,' the research is spearheaded by graduate student Vaishakhi Trivedi under the mentorship of Dr Kumar Prabhash and Dr Amit Dutt. 'Our work not only adds data to global cancer databases —it also redefines what is known about thyroid cancer in the Indian population,' Dr Dutt said. The rogue gene in the most common thyroid cancer The study concerns papillary thyroid cancer (PTC), which accounts for 80-85 per cent of all thyroid cancer cases in India. This is considered treatable. The team analysed DNA from 100 Indian patients and found mutations in the DUOX2 gene found in nearly nine per cent of cases. 'This gene, previously known for its role in thyroid hormone production, now appears to be a genetic red flag for recurrence and poor prognosis. This is the first time DUOX2 has been implicated as a predisposing factor in PTC. It offers an opportunity for early detection and potentially life-saving interventions,' Dr Dutt said. Study uncovers two distinct molecular subtypes The study even identified two different subtypes associated with aggressive cancer and high recurrence. The BRAF-RAS-driven subtype makes up 62 per cent of cases and is identified by mutations that are often tied to more aggressive tumour behaviour. The iBR (Independent of BRAF-RAS) subtype is a newly-defined category. 'This group lacks traditional mutations but shows alarming signs of treatment resistance and high recurrence. It is marked by alterations in genes like SMAD4 and TG — a previously uncharted territory for thyroid oncologists,' said Dr Dutt. This dual classification signals a new era of care where treatments are tailored to the patient's genetic profile rather than a one-size-fits-all approach. Cracking the genetic code of an aggressive form of thyroid cancer While PTC is common and often curable, anaplastic thyroid cancer (ATC) is its deadly cousin — rare, fast-moving and resistant to nearly every treatment in the book. The research team examined 68 samples and found mutations in the THRA gene in 11 per cent of Indian patients. This is in sharp contrast to Caucasian datasets. 'THRA, a gene tied to thyroid hormone signalling, appears to be a key player in cellular plasticity or the process by which cancer cells morph, lose their identity and become more aggressive. THRA mutations are like flipping the switch. They make the cancer harder to kill but they also give us a target. That's a rare silver lining,' Dr Prabhash explained. What this means for Indian patients — and the world These findings offer practical methods of how thyroid cancers are diagnosed, treated and managed in Indian patients. 'Patients with DUOX2 mutations could be monitored proactively, much like BRCA testing in breast cancer. This may help in diagnosing aggressive PTC early and prevent a relapse,' Dr Dutt said. Researchers also added that therapies that restore THRA function may finally give ATC patients a fighting chance. 'We need a personalised roadmap for thyroid cancer. With the promise of advanced tools like CRISPR gene editing and small-molecule inhibitors, these discoveries could soon migrate from the lab bench to the bedside,' the researchers said. 'Genetic profiling should be as routine as a biopsy,' said Vaishakhi Trivedi. 'We have the science. Now we need the systems to support it.' Anuradha Mascarenhas is a journalist with The Indian Express and is based in Pune. A senior editor, Anuradha writes on health, research developments in the field of science and environment and takes keen interest in covering women's issues. With a career spanning over 25 years, Anuradha has also led teams and often coordinated the edition. ... Read More
